DOCS Price Prediction Next Week
Technical Analysis: Based on the technical indicators, DOCS shows strong bullish momentum with RSI at 87.85, indicating overbought conditions. The MACD of 4.53 confirms the positive trend. The stock is trading significantly above both its 20-day SMA (58.45) and 200-day SMA (39.96), suggesting a robust uptrend.
Recent Performance & News Impact: DOCS surged 34.06% last week following strong Q3 FY2025 results. The company reported:
- EPS of $0.45 vs $0.34 consensus
- Revenue of $168.6M, up 25% YoY
- Record EBITDA margin of 60.5%
Analyst Reactions: Multiple analysts have raised their price targets:
- Goldman Sachs: $80 (from $58)
- Needham: $82 (from $65)
- Raymond James: $83 (from $65)
- Leerink Partners: $90 (from $60)
Price Prediction for Next Week: Based on Fibonacci levels:
- Support levels: S1: $56.37, S2: $49.30
- Resistance levels: R1: $79.25, R2: $86.32
- Pivot: $67.81
Trading Recommendation: SELL. Despite strong fundamentals and analyst upgrades, the stock is showing significant overbought conditions after the recent 34% surge. The RSI at 87.85 suggests a potential pullback is likely. Traders should consider taking profits at current levels ($79-80) and wait for a healthier entry point near the first support level of $56.37.
The stock is likely to consolidate between $75-82 next week, with potential downside risk to $70 as profit-taking occurs. A break below $70 could accelerate the decline toward the pivot point at $67.81.
DOCS Similar Chart Price Prediction
The price of DOCS is predicted to go up 33.99%, based on the high correlation periods with PBYI. The similarity of these two price pattern on the periods is 96.37%.
DOCS
PBYI
Up: 33.99%Similarity: 96.37%
DOCS Revenue Forecast
DOCS EPS Forecast
DOCS FAQs
What is bull’s view on DOCS?
What is bear's view on DOCS?
What is DOCS revenue forecast for next quarter？
What is DOCS eps forecast for next quarter？
DOCS Analyst's Forecast
Steven Valiquette
Mizuho
Hold
2025-02-10
Price Target
$55 → $65
Downside
-21.82%
Mizuho raised the firm's price target on Doximity to $65 from $55 and keeps a Neutral rating on the shares. The company reported its third consecutive "beat and raise" quarter as it continues to increase engagement with physicians on its app, the analyst tells investors in a research note. The firm believes Doximity's new pharma client portal, which allows clients to more easily track marketing spend virtually real-time, is another key factor in accelerating revenue growth.
Stan Berenshteyn
Wells Fargo
Hold
2025-01-13
Price Target
$41 → $43
Downside
-13.5%
Scott Schoenhaus
Keybanc
Buy
2025-01-08
Price Target
$70 → $65
Upside
+18.18%
